CELLAVISION AB (publ) Interim report for the period January 1 - June 30, 2009

2009-07-15 - English

  •    Net sales for the period amounted to SEK 42.7 million (41.3), an increase of 2 %. The second quarter accounted for SEK 20.7 million (22.8) of this amount.
  •    The operating profit for the period was SEK 1.8 million (2.8) and for the second quarter SEK 1.0 million (1.5).
  •    Earnings per share for the period amounted to SEK 0.06 (0.11).
  •    Cash and cash equivalents were SEK 9.3 million (16.9) by the end of the quarter.
  •    The new analyzer CellaVision® DM1200 was presented in Europe, and the first orders were taken.
  •    CellaVision was awarded the SwedenBIO Award for its successes during 2008.
  •    CellaVision's Japanese subsidiary received its first order.
  •    CellaVision qualified for trade on the NASDAQ OMX First North Premier.
    CEO's comment
    "CellaVision's products are still receiving a great deal of attention on our main markets. The hospital market is being increasingly affected by the global financial crisis and decisions to purchase are taking longer, which is most apparent on the US market. Having said that, it is worth noting that we are still showing a positive result despite a financially unstable world market," says Yvonne Mårtensson, CEO of CellaVision.
    "Our new product, the CellaVision DM1200 provides CellaVision with a wider and stronger range of products, giving us a more competitive edge. The product was shown in Europe for the first time during this quarter. The analyzer was very well received and CellaVision has already taken its first orders from Sysmex in Europe. We are now waiting for the product to be ready for sale in the end of July, and the next step will be to obtain the approvals needed to sell the CellaVision DM1200 on other markets. The development of this product has demanded large resources during the period, which has contributed to the negative cash flow."
    "Our investments in our own sales organizations in Japan and North America have resulted in the first Japanese order received from one of Japan's largest laboratory chains as well as several important orders in Canada. North America accounted for 54 % during the period."
    For more information please contact: 
    Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.com 
    Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.com
    Download the report by pressing the link below.

    PDF version: CellaVision AB - Interim report for the period January 1 - June 30, 2009

    Subscribe to updates

    It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

    Click here to register

    Information request

    Are you looking for some particular information about our company or our business?

    Click here to get in touch


    ABG Sundal Collier AB
    Sten Gustafsson
    +46 8 566 286 93

    Pareto Securities AB
    Christian Lee
    +46 8 402 52 67


    Access our Student Resources

    To access this resource, please provide the following information about yourself.